<DOC>
	<DOCNO>NCT02049437</DOCNO>
	<brief_summary>The study phase I/II , double-blind , placebo-controlled , randomized cross-over clinical trial tocilizumab ( TCZ ) placebo HIV-infected subject receive antiretroviral therapy suppress viral replication CD4+ T cell count ≥350 ≤1,000 cells/mm3 )</brief_summary>
	<brief_title>AIDS 347 : IL-6 Blockade Treated HIV Infection</brief_title>
	<detailed_description>DESIGN The study phase I/II , double-blind , placebo-controlled , randomized cross-over clinical trial tocilizumab ( TCZ ) placebo HIV-infected subject receive antiretroviral therapy suppress viral replication CD4+ T cell count ≥350 ≤1,000 cells/mm3 ) DURATION 48 week ( 40 week cross-over treatment period ) total per subject . SAMPLE SIZE 30 subject complete data week 30 . Up 36 subject may enrol order achieve estimate final sample size 30 participant complete data week 30 . POPULATION HIV-infected male female subject 18 60 year age receive combination antiretroviral therapy ( ART ) without change 24 week prior enrollment ( change reason virologic failure allow 8 week prior enrollment ) , suppress plasma HIV RNA ( &lt; 200 copies/mL , one blip &lt; 1,000 copies/mL permit ) least 96 week CD4+ T-cell count ≥350 ≤1,000 cells/mm3 time study enrollment . REGIMEN Subjects randomize 1:1 one follow arm : ARM A : TCZ , 4 mg/Kg IV infusion 60 minute ( exceed 400 mg ) study entry , follow TCZ , 8 mg/Kg IV infusion 60 minute ( exceed 800 mg ) week 4 , 8 THEN placebo IV infusion week 20 , 24 , 28 . ARM B : Placebo IV infusion study entry follow placebo IV infusion week 4 8 , THEN TCZ , 4 mg/Kg ( exceed 400 mg ) IV infusion 60 minute week 24 , follow TCZ , 8 mg/Kg ( exceed 800 mg ) IV infusion 60 minute week 24 28 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Inclusion Criteria 4.1.1 Men woman age 1860 year . 4.1.2 Ability willingness communicate English Spanish 4.1.3 Ability willingness subject provide inform consent . 4.1.4 Ability willingness provide adequate locator information . 4.1.5 HIV1 infection , document licensed rapid HIV test HIV enzyme chemiluminescence immunoassay ( E/CIA ) test time study entry confirm licensed Western blot , second antibody test method rapid HIV E/CIA ; HIV1 antigen ; plasma HIV1 RNA viral load . 4.1.6 Receiving stable antiretroviral regimen consist 3 drug belong two class , one must protease inhibitor , integrase inhibitor , nonnucleoside reverse transcriptase inhibitor , without change due virologic failure past 24 week , plan change antiretroviral regimen 40 week follow enrollment . If regimen include protease inhibitor , ritonavir approve boosting agent know increase trough level protease inhibitor least 50 % must also part regimen . NOTE A : Changes antiretroviral regimen 8 week prior enrollment allow plasma HIV RNA &lt; 50 copies/mL time change , reason change suspicion documentation virologic failure , criterion virologic control , outline criterion 4.1.9 , meet . NOTE B : For purpose protocol , `` change due virologic failure '' define follow event combination thereof happen patient receive uninterrupted combination antiretroviral therapy include least three agent belong least two class : ) plasma HIV RNA &gt; 200 copies/mL two consecutive occasion ; b ) treat physician determines give plasma HIV RNA value indicative suggestive virologic failure , recommend patient 's regimen modify result ; c ) genotypic phenotypic antiretroviral resistance test identifies presence resistance component patient 's regimen present , physician recommend patient 's regimen modify result . 4.1.7 For subject positive HBcAb : • An antiretroviral regimen contain one follow medication : lamivudine , emtricitabine , tenofovir . 4.1.8 Screening CD4+ Tcell count ≥350 cells/mm3 ≤1,000 cells/mm3 perform laboratory Clinical Laboratory Improvement Amendments ( CLIA ) certification equivalent . 4.1.9 HIV1 RNA &lt; 200 copies/mL every time plasma HIV RNA obtain , few twice , 96 week prior enrollment . NOTE : One plasma HIV RNA 200 copies/mL low 1,000 copy 96 week prior enrollment permissible flank two measurement 200 copy . The HIV1 RNA screen must &lt; 50 copies/mL . 4.1.10 The following laboratory value obtain within 60 day prior entry : Hgb ≥10 g/dL Platelet count &gt; 100,000/mm3 Absolute neutrophil count ( ANC ) ≥2,000 cells/mm3 Aspartate aminotransferase ( AST ) [ serum glutamic oxaloacetic transaminase ( SGOT ) ] &lt; 1.5x ULN Alanine aminotransferase ( ALT ) [ serum glutamic pyruvic transaminase ( SGPT ) ] &lt; 1.5x ULN For subject consent undergo rectal tissue sampling : International normalized ratio ( INR ) &lt; 1.7 Total bilirubin &lt; 3.0 mg/dL , EXCEPT subject receive atazanavir For subject receive atazanavir : Direct bilirubin ≤1.0 mg/dL Calculated GFR ≥60 mL/min/1.73m2 4.1.11 Female subject reproductive potential must negative serum urine pregnancy test study entry must affirm intend become pregnant duration study . NOTE : For purpose protocol , female subject reproductive potential define one reach menarche , postmenopausal least 24 consecutive month ( i.e. , menses within precede 24 month ) , undergone surgical sterilization ( e.g. , hysterectomy , tubal ligation , bilateral oophorectomy ) . 4.1.12 Female subject reproductive potential participate sexual activity could lead pregnancy must agree use least one follow form birth control least 30 day prior study entry 30 day final study visit : Condoms ( male female ) without spermicidal agent Diaphragm cervical cap spermicide PLUS least one following : An FDAapproved copper intrauterine device ( IUD ) , e.g . ParaGard® , FDAapproved hormonereleasing IUD , e.g . Mirena® An FDAapproved transdermal hormonal contraceptive , e.g . OrthoEvra® An FDAapproved injectable hormonal contraceptive , e.g . DepoProvera® An FDAapproved hormonal contraceptive vaginal ring form , e.g . NuvaRing® An FDAapproved implantable hormonal contraceptive , e.g . Implanon® Jadelle® NOTE A : Oral hormonal contraceptive , either combine progestinonly , acceptable second contraceptive method . NOTE B : Women reproductive potential use hormonal contraceptive include may consider switch contraceptive one approve form , require consultation primary healthcare provider . Study investigator prescribe recommend specific form contraception study participant . The study cover cost contraceptive . 4.1.13 Female subject reproductive potential [ i.e. , woman postmenopausal least 24 consecutive month woman undergone surgical sterilization ( e.g. , hysterectomy , tubal ligation , bilateral oophorectomy ) ] eligible without require use contraceptive . Acceptable documentation sterilization , contraception method , menopause reproductive potential patientreported history time prior screening . 4.1.14 Subjects must determine investigator least one fully active regimen available regimen receive study entry . The determination whether alternative regimen available must take account subject 's antiretroviral history previously obtain resistance test . A valid alternative regimen must meet recommendation active regimen outline current DHHS guideline Use Antiretroviral Agents HIV1Infected Adults Adolescents ( 93 ) . Exclusion Criteria 4.2.1 History one follow opportunistic infection time past , demonstrate either patientreported physiciandocumented diagnosis AND initiation specific treatment applicable : Tuberculosis , pulmonary extrapulmonary Nontuberculous mycobacterial infection , disseminate extrapulmonary Pneumocystis jirovecii pneumonia Coccidioidomycosis , disseminate extrapulmonary Cryptococcosis , extrapulmonary Cryptosporidiosis isosporiasis , chronic intestinal ( great 1 month 's duration ) Cytomegalovirus disease ( liver , spleen , lymph node ) include retinitis loss vision Histoplasmosis , disseminate extrapulmonary Kaposi 's sarcoma Lymphoma , Burkitt 's immunoblastic , regardless anatomical location Lymphoma , primary brain Progressive multifocal leukoencephalopathy Toxoplasmosis brain 4.2.2 Latent tuberculosis infection , define positive borderline FDAapproved interferongamma release assay ( IGRA ) . 4.2.3 Pregnant breastfeeding . 4.2.4 Active local systemic infection ( define require systemic antibiotic medical surgical treatment ) time enrollment . 4.2.5 Use systemic cancer chemotherapy radiation therapy , immunosuppressive immunomodulatory therapy ( e.g. , interferon , tumor necrosis factor antagonist , interleukin ) investigational therapy within 90 day prior study entry continue indication medication . A list prohibit study medication provide appendix 1 Manual Operations ( MOPS ) . NOTE A : Use inhale nasal steroid , equivalent 10 mg prednisone less per day le 2week course steroid exclusionary . NOTE B : A single course 1 % hydrocortisone cream equivalent apply 3 time day &lt; 10 square inch area &lt; 2 week permit . The investigator determine form limit , shortterm topical steroid use expect interfere significantly study objective therefore exclusionary . 4.2.6 Receipt live attenuate vaccine within 30 day prior study entry expect need vaccines time 30 day study . 4.2.7 Known allergy/sensitivity hypersensitivity component study drug formulation . 4.2.8 Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . 4.2.9 Serious illness require systemic treatment and/or hospitalization within 45 day prior study entry . 4.2.11 Known cirrhosis severe liver disease ( e.g. , ascites , encephalopathy , history variceal bleeding ) . 4.2.12 Active hepatitis B ( positive HBsAg , HBV DNA , HBeAg ) hepatitis C ( positive HCV antibody positive HCV RNA plasma ) document screen visit . NOTE A : For purpose document hepatitis B status , HBsAg HBV DNA obtain 6 month prior date screen visit acceptable EXCEPT subject positive HBcAb screening ( see Note B ) . A negative HBeAg period absence HBsAg HBV DNA sufficient evidence HBVnegative status . If clinically obtain test available screening , HBsAg draw together evaluation visit . NOTE B : For subject positive HBcAb screening , HBV DNA limit quantification time screen study entry require . NOTE C : For purpose document HCV status , negative HCV antibody obtain 6 month prior date screen visit sufficient . For subject positive HCV antibody , HCV RNA measurement require . 4.2.13 History diverticulitis , intestinal perforation , distal intestinal obstruction , low gastrointestinal bleeding . 4.2.14 An antiretroviral regimen contain maraviroc study entry . 4.215 History demyelinate disorder multiple sclerosis chronic demyelinate polyneuropathy time past . 4.2.16 A trough level protease inhibitor ( boost dose ritonavir ) nonnucleoside reverse transcriptase inhibitor include subject 's antiretroviral regimen screen low limit steadystate trough level range observe publish study , accord Table 2 , . Table 2 : Cutoffs select antiretroviral trough level Drug Lower limit range ( level screen exclusionary ) Efavirenz ( 94 ) 1 µg/mL Nevirapine ( 94 ) 3 µg/mL Etravirine ( 95 ) 75 ng/mL Rilpivirine ( 96 ) 4 ng/mL Atazanavir/r ( 94 ) 0.15 µg/mL Darunavir/r ( 96 ) 1036 ng/mL Lopinavir/r ( 94 ) 1 µg/mL Amprenavir ( 94 ) 0.4 µg/mL Fosamprenavir/r ( 94 ) 0.4 µg/mL Indinavir/r ( 94 ) 0.1 µg/mL Saquinavir SGC/r ( 94 ) 0.1 µg/mL Nelfinavir ( 94 ) 0.8 µg/mL 4.2.17 Active malignant disease , resect basal cell carcinoma skin . 4.2.18 For subject consent undergo rectal tissue sampling : History bleed diathesis kind , contraindication lower GI endoscopy Major GI tract surgery within 45 day prior study entry . Minor procedure involve anal canal condyloma ablation , hemorrhoidectomy , anoscopy permit cleared responsible surgeon . Continued need , use 7 day prior schedule flexsig procedure , follow medication : Aspirin , systemic antiplatelet agent , 4 dos NSAIDs Warfarin , heparin , thrombin inhibitor , factor Xa inhibitor , systemic thromobolytics fibrinolytics . A list prohibit medication flexsig procedure find appendix MOPS . A bridge course shortacting lowmolecular weight heparin within 7day preprocedure window patient receive chronic systemic anticoagulant safely maintain anticoagulation several day permit cleared subject 's primary healthcare provider UHCMC Digestive Health Institute . Abnormalities colorectal mucosa , significant colorectal symptom , opinion clinician represent contraindication biopsy ( include limit presence unresolved injury , infectious inflammatory condition local mucosa )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>HIV</keyword>
	<keyword>Immune failure</keyword>
	<keyword>Tocilizumab</keyword>
	<keyword>ACTEMRA</keyword>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>HAART</keyword>
</DOC>